Compare HALO & HIMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HALO | HIMS |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 7.8B |
| IPO Year | 2001 | 2019 |
| Metric | HALO | HIMS |
|---|---|---|
| Price | $78.05 | $33.40 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 15 |
| Target Price | ★ $78.64 | $30.46 |
| AVG Volume (30 Days) | 1.8M | ★ 14.8M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | $151,862,000.00 | ★ $2,347,637,000.00 |
| Revenue This Year | $28.24 | $19.82 |
| Revenue Next Year | $12.56 | $19.23 |
| P/E Ratio | $63.51 | ★ N/A |
| Revenue Growth | N/A | ★ 59.00 |
| 52 Week Low | $55.64 | $13.74 |
| 52 Week High | $82.26 | $70.43 |
| Indicator | HALO | HIMS |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 49.02 |
| Support Level | $67.12 | $29.39 |
| Resistance Level | $82.24 | $36.22 |
| Average True Range (ATR) | 2.46 | 2.46 |
| MACD | -0.33 | -0.53 |
| Stochastic Oscillator | 46.95 | 17.21 |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.